HSF1 binds to 14-3-3 after serum stimulation and requirement for HSF1 phosphorylation on serines 303 and 307. (A) Association of 14-3-3 with HSF1 is enhanced by serum. GST-tagged 14-3-3ɛ expression vector was transfected in equivalent amounts into four subconfluent cell cultures, and plates were serum starved as described in Materials and Methods. Subsequently, the cultures were harvested without stimulation (lanes 1 and 2) or after stimulation with 20% fetal calf serum. 14-3-3ɛ-GST fusion proteins were then purified by GSH affinity chromatography, fractionated by SDS-PAGE, and analyzed for their levels and associated proteins with anti-GST and anti-HSF1 antibodies as indicated. As a control, extracts from the two serum-stimulated duplicate cultures of lanes 3 and 4 were subjected to GSH affinity chromatography in the presence of 0.1% SDS-0.5 M NaCl (lanes 5 and 6). As additional control pull-downs, protein A-Sepharose was used in place of GSH-Sepharose for these two extracts. Finally, total extracts from each of the four transfections were analyzed by Western and enhanced chemiluminescence with antibodies against activated MEK or ERK or with control antibodies for ERK2 or HSF1 (bottom). For direct assessment of the relative levels of 14-3-3ɛ-GST expression, the same extracts were also blotted with anti-pan 14-3-3 antisera, which recognizes both the transfected 14-3-3ɛ-GST chimera and the endogenous 14-3-3 isoforms. To this end, please note the low levels of exogenous 14-3-3 expression in comparison with its endogenous counterpart. Experiments were carried out twice with reproducible results. (B) Association of 14-3-3 with HSF1 in vivo. 14-3-3ɛ was transiently expressed in cells as a GST fusion protein as described in Materials and Methods. As a control, in a parallel transfection, GST propeptide was expressed alone as indicated. Cycling cultures of each of the three transfections were harvested, solubilized in extraction buffer, and subjected to GSH affinity chromatography (lanes 1, 3, and 5). As controls, parallel pull-downs containing 0.1% SDS-0.5 M NaCl in the extraction and wash buffer were included (lanes 2, 4, and 6). After SDS-PAGE, anti-GST and anti-HSF1 blotting was performed to verify the levels of 14-3-3ɛ-GST expression and recovery and associated HSF1. For assessment of protein expression, control Western blots of total cellular extracts with anti-pan 14-3-3 antisera or antibodies directed against HSF1 are also shown (bottom panels). (C) HeLa cells were serum starved and pretreated with 50 μM PD98059 before stimulation with 10% FBS-Ham F-12 medium. Cells were then lysed in immunoprecipitation buffer and probed by immunoprecipitation with anti-HSF1 polyclonal antibody (A68-3), followed by immunoblotting with anti-14-3-3ɛ monoclonal antibody as indicated (upper panel). The blot was then reprobed to confirm efficient immunoprecipitation of HSF1 with anti-HSF1 polyclonal antibody (A68-3) (bottom panel). Experiments were carried out twice with reproducible findings. (D) Binding of 35S-labeled 14-3-3ɛ to synthetic peptides. Microtiter wells were coated with synthetic phosphorylated and unphosphorylated peptides derived from the proline-rich domain of HSF1 (phospho-S303-S307, phospho-S307, phospho-S303, and unphospho-HSF1) as described in Materials and Methods. Different concentrations of 35S-labeled 14-3-3ɛ protein (160 and 400 ng/ml) were then added to the coated microtiter wells and incubated at 22°C for 2 h. After an extensive washing, bound proteins were extracted and measured by liquid scintillation counting. The results are expressed as the mean of the 35S-labeled 14-3-3ɛ activity extracted from triplicate wells ± the SD. Experiments were carried out three times with close agreement between experiments. (E) Competitive binding of phosphorylated HSF1 peptides to 35S-labeled 14-3-3ɛ protein. 35S-labeled 14-3-3ɛ (160 ng/ml) was incubated first with a 100 μM concentration of each of the phosphorylated or unphosphorylated peptides for 1 h at 22°C and then added to microtiter wells coated with each of the phosphorylated peptides (phospho-S303-S307, phospho-S307, and phospho-S303) (as described above), followed by incubation at 22°C for 2 h. After extensive washing of the plates, bound proteins were extracted and assayed by liquid scintillation counting. Competition experiments were also carried out with phospho-Cdc25c-S216, a well-characterized 14-3-3-binding peptide, as a positive control as indicated. Each competition assay was carried out in duplicate. The entire experiment was carried out three times with reproducible findings each time. (F) Effect of phospho-S303 and phospho-S307 peptides on the association of 14-3-3 with FLAG-HSF1. Purified 14-3-3-GST was mixed with serum-stimulated cell extracts prepared from cells expressing either FLAG-HSF1 (lane 1) or FLAG propeptide alone (lane 4). To test the potential effect of phosphorylation on the association of 14-3-3ɛ with FLAG-HSF1, parallel reactions included synthetic HSF1-based peptides phosphorylated either on Ser-303 (lanes 2 and 5) or Ser-307 (lanes 3 and 6). After washes, the 14-3-3ɛ-GST and associated FLAG-HSF1 were fractionated by SDS-PAGE and blotted with anti-FLAG and anti-14-3-3ɛ antibodies as indicated. Below each lane the densitometry value of bound FLAG-HSF1 is indicated as a percentage value, with a control (100%) in lane 1. As a control, 10-μl aliquots of the reactions taken before washes were also assessed for the levels of FLAG-HSF1 (bottom). Experiments were repeated reproducibly three times.